SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer

Clinical trial NCT05445908 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05445908
Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Triple-negative Breast Cancer and HR+/HER2- BC

Start date: 2022-08-17
Primary completion: 2027-09-01
Enrollment: 175

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.